GNP announces conference and trade show for June
VALLEY FORGE, Pa. — AmerisourceBergen’s Good Neighbor Pharmacy, a network of more than 3,500 community pharmacies nationwide, on Tuesday launched ThoughtSpot, a national conference and trade show focused on helping community pharmacists grow their business. The conference will be held from June 20 to 23 at Caesars Palace in Las Vegas.
"ThoughtSpot is more than just a purchasing event or a place to get CE credits — it’s a conference where community pharmacists can find resources and ideas to help their businesses thrive," Good Neighbor Pharmacy president Michael Cantrell said. "Our attendees have told us they want to learn about best practices in areas like pharmacy staffing, increasing share of profitability from nonprescription items and practical use for social media. ThoughtSpot will address all those topics in a way that allows attendees to begin producing results the moment they arrive home."
ThoughtSpot by Good Neighbor Pharmacy will focus on providing community pharmacists and their staff actionable tools to help their business, GNP reported. General session presentations will provide insight about where the community pharmacy industry is headed. Continuing education seminars on such issues as learning the pros and cons of expanding business opportunities or understanding the latest updates in diabetes management will be available for all attendees. Hands-on learning labs and interactive panels also will be available to provide practical business and clinical information.
More than 200 pharmaceutical manufacturers and suppliers are expected to attend.
Online registration for ThoughtSpot is at Thoughtspot2012.com.
Hyperion buys rights to drug for rare genetic diseases
SOUTH SAN FRANCISCO, Calif. — Hyperion Therapeutics has purchased rights to a drug for treating genetic metabolic disorders, the company said.
Hyperion announced the purchase of Ravicti (glycerol phenylbutyrate) from Ucyclyd Pharma, a subsidiary of Medicis Pharmaceutical.
The drug is awaiting Food and Drug Administration approval for the treatment of urea cycle disorders, a class of genetic disorders that affects 1-in-10,000 births and result from deficiency in enzymes involved in the urea cycle, the body’s primary means of removing ammonia from the bloodstream. Left untreated, the conditions can result in brain damage, coma and death.
Financial terms of the deal were not disclosed. Hyperion also has the option of buying rights to two other drugs in 2013.
FDA approves J&J HIV drug in children
TITUSVILLE, N.J. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating HIV in children.
J&J’s Janssen Therapeutics division announced Tuesday the FDA approval of Intelence (etravirine) in patients ages 6 years to younger than 18 years with HIV-1 who have taken other therapies but whose infection has become resistant to treatment. The drug already was approved for adults.
"This indication fulfills an important need in the U.S. among treatment-experienced young children and adolescents living with HIV," Janssen Therapeutics medical director David Anderson said. "This approval also expands the treatment options Intelence offers and reinforces our company’s commitment to serving the diverse needs of the HIV treatment community."